Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -15,20 +15,8 @@
15	15	(((
16	16	= What is this about and what can I find here? =
17	17
18		-= **Overview** =
	18	+== **Overview** ==
19	19
20		-T
21		-
22		-The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient.
23		-
24		-This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**.
25		-
26		-The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**.
27		-
28		-=== **Project Aim** ===
29		-
30		-The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**.
31		-
32	32	The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
33	33
34	34	* **Axis 1**: Etiology (genetic or other causes of diseases).
...	...	@@ -35,6 +35,10 @@
35	35	* **Axis 2**: Molecular Markers (biomarkers).
36	36	* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
37	37
	26	+
	27	+[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
	28	+
	29	+
38	38	This methodology enables:
39	39
40	40	* Greater precision in diagnosis.
...	...	@@ -41,22 +41,10 @@
41	41	* Integration of incomplete datasets using AI-driven probabilistic modeling.
42	42	* Stratification of patients for personalized treatment.
43	43
44		-== **The Role of AI-Powered Annotation** ==
45		-
46		-To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which:
47		-
48		-* **Assigns structured metadata tags** to diagnostic features.
49		-* **Provides real-time contextual explanations** for AI-based classifications.
50		-* **Tracks longitudinal disease progression** using timestamped AI annotations.
51		-* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis).
52		-* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO).
53		-
54	54	== **The case of neurodegenerative diseases** ==
55	55
56	56	There have been described these 3 diagnostic axes:
57	57
58		-[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
59		-
60	60	* (((
61	61	**Axis 1: Etiology**
62	62
...	...	@@ -86,6 +86,10 @@
86	86	* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
87	87	* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
88	88
	69	+== Who has access? ==
	70	+
	71	+We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
	72	+
89	89	== How to Contribute ==
90	90
91	91	* Access the `/docs` folder for guidelines.
...	...	@@ -97,17 +97,9 @@
97	97	* Develop interpretable AI models for diagnosis and progression tracking.
98	98	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
99	99	* Foster collaboration among neuroscientists, AI researchers, and clinicians.
100		-
101		-== Who has access? ==
102		-
103		-We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
104	104	)))
105	105
106	106
107		-
108		-
109		-
110		-
111	111	(% class="col-xs-12 col-sm-4" %)
112	112	(((
113	113	{{box title="**Contents**"}}